Tec-DR and Tal-DR for Multiple Myeloma
(MajesTEC-7 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing two new drug combinations to see if they work better than the current standard treatment for multiple myeloma. The new treatments aim to help the immune system find and destroy cancer cells more effectively.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does mention that you should not have received any prior therapy for multiple myeloma or smoldering myeloma, except for a short course of corticosteroids. It's best to discuss your current medications with the trial team.
How is the Tec-DR and Tal-DR drug for multiple myeloma different from other treatments?
The Tec-DR and Tal-DR drug for multiple myeloma is unique because it combines daratumumab, a monoclonal antibody targeting CD38, with teclistamab, a bispecific antibody, which may offer a novel mechanism of action by engaging the immune system in a different way compared to standard treatments. This combination could potentially enhance the effectiveness of the treatment by targeting multiple pathways involved in the disease.12345
What data supports the effectiveness of the drug combination Tec-DR and Tal-DR for treating multiple myeloma?
Research shows that combining daratumumab with lenalidomide and dexamethasone significantly improves outcomes for patients with multiple myeloma, including longer periods without disease progression and higher response rates. This suggests that similar combinations, like Tec-DR and Tal-DR, could also be effective.12678
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
This trial is for adults with newly diagnosed multiple myeloma who can't have high-dose chemotherapy with stem cell transplant due to age or other health issues. They should be able to perform daily activities (ECOG score 0-2) and must not plan on pregnancy or fathering children during the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Tec-DR or Tal-DR or DRd regimen, with cycles of 28 days each
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Daratumumab
- Dexamethasone
- Lenalidomide
- Teclistamab
Daratumumab is already approved in European Union, United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University